The final results of the KEYNOTE-585 study presented at ESMOGI24

ESMO shared on LinkedIn:

“The final results of the KEYNOTE-585 study presented at ESMOGI24 suggest that the current treatment standard for resectable gastric/gastro-oesophageal junction cancers should remain unchanged.

Event-free survival was not significantly improved with pembrolizumab plus chemotherapy compared to placebo plus chemotherapy or placebo plus FLOT.

According to Elizabeth Smyth however, the increase in the pathological complete response rate seen with the addition of pembrolizumab suggests it may improve response to chemotherapy in at least some patients.

To learn more about this topic, read the ESMO Daily Reporter article.”

Source: ESMO/LinkedIn